Laparoscopy for gastric cancer
Upcoming SlideShare
Loading in...5

Laparoscopy for gastric cancer






Total Views
Views on SlideShare
Embed Views



1 Embed 1 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • A prospecitvely maintained database of all patients treated for gastric adenocarcinoma at Memorial Hospital between 1992-2002 was used. In general, the policy was to perform staging laparoscopy if there was no definitive evidence of M1 disease on CT scanning and there was no bleeding or obstruction that required laparotomy irrespective of disease-stage. Accordingly, 718 patients underwent laparoscopy. After excluding selected patients on investigational protocols, there were 147 patients who had M1 disease and no further procedure. Of the laparoscopic M0 group, 18 patients did not have resection because of M1 disease at laparotomy and were included in the study group giving a total of 165 patients. Patients with no resection because of locally advanced primary tumors but no M1 were specifically excluded .
  • Approximately one-quarter of patients each had primary tumors located at either the GEJ or in the gastric body. For the remaining half, tumors were approx. equally distributed in the proximal stomach, antrum or involved the entire stomach.
  • M1 disease was limited to the peritoneum adjacent to the stomach in 8%. There were few distant peritoneal metastasis in about one-third of patients and disseminated peritoneal metastasis in another one-third. Metastasis were confined to the liver in 10%. There was a combination of liver and peritoneal metastasis in 16%.
  • During the follow-up period, 41 of the 97 patients, 40%, had an intervention on the primary tumor. Intervention was required for gastric luminal obstruction or provision of supplemental nutrition in 32 patients. 8 patients had intervention for bleeding and one patients for perforation of the primary tumor.
  • In summary, intervention on the primary tumor was necessary in 42% of patients. Only 8% had laparotomy and the remaining were treated with endoscopic procedures or radiation therapy only. Median survival of the entire cohort was 10 months. Patients with a low burden of peritoneum only disease or good FPS had significantly longer survival.
  • Survival data were available for 156 patients. Their estimated median survival was 10 months with a one-year survival of about 40% and two-year survival of 4% . The maximum survival was 37 months.

Laparoscopy for gastric cancer Laparoscopy for gastric cancer Presentation Transcript

  • Laparoscopy for Gastric Cancer Abeezar I. Sarela MBBS FRCS Consultant in Upper Gastrointestinal & Minimally Invasive Surgery The General Infirmary at Leeds, United Kingdom Massachusetts General Hospital, August 17, 2006
  • The General Infirmary at Leeds
  • Chairs of Surgery in Leeds Berkeley G.A. Moynihan FRCS
    • Pioneer abdominal surgeon
    • Founder: Association of Surgeons of GB
    • Founder: The British Journal of Surgery
  • Chairs of Surgery in Leeds Phillip Allison FRCS
  • Chairs of Surgery in Leeds John C. Goligher FRCS
    • Eminent colorectal surgeon
    • Peptic ulcer surgery
  • Chairs of Surgery in Leeds Contemporary
    • David Johnson FRCS
    • Pioneer of HSV and bariatric surgery
    • Pierre J. Guillou FRCS
    • PI: MRC CLASICC Trial
    • Michael J. McMahon FRCS
    • President, Association of Laparoscopic Surgeons of GB
  • Upper GI & Laparoscopic Surgery Current Unit in Leeds
    • Simon P. Dexter FRCS
    • Michael J. McMahon FRCS
    • Abeezar I. Sarela FRCS
    • Henry M. Sue-Ling FRCS
  • Gastric Cancer Role of Laparoscopy
    • Staging
      • for carcinoma
    • Curative Resection
      • for carcinoma and GIST
    • Palliation
    • Treatment of sequels of open gastrectomy
      • Incisional hernia
      • Intestinal obstruction
  • Staging Philosophy
    • CT staging: False-negative results
    • M1 is incurable disease
    • Treatment-intent
      • Optimise quality of life
      • Prolong length of survival
      • Minimise treatment-related complications
  • Laparoscopic Staging of Gastric Carcinoma Memorial Sloan Kettering Cancer Center Experience
    • Period: 1993-2002
    • Gastric or GOJ carcinoma 1748 patients
    • Selection criteria:
      • Clinically & radiologically M0
      • Acceptable risk for major operation
      • No obstruction or bleeding
    • Laparoscopy 657 patients
    • Laparoscopic M1 23%
    • Laparoscopic false-negative M0 9%
    • Sarela AI (Brennan MF) et al. Am J Surg. 2006;191:134-38
  • Laparoscopic Staging
    • For patients with laparoscopic M1 disease, is no resection of the primary tumour associated with:
    • High incidence of complications?
    • Shorter survival?
  • Laparoscopic M1Gastric Carcinoma, No Resection Memorial Sloan Kettering Cancer Center Experience Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
  • Laparoscopic M1, No resection 165 Patients Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95 Primary Tumour Location
  • Laparoscopic M1, No Resection Peritoneal metastasis P1: adjacent to stomach P2: few distant lesions P3: disseminated 165 patients 9%
  • Laparoscopic M1, No Resection Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95 Intervention
  • Laparoscopic M1, No Resection
    • Intervention 42%
    • Laparotomy 8%
    • Mortality 1%
    Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
  • Laparoscopic M1, No Resection Survival Median survival: 10 months One year survival: 39% 156 patients
  • M1 Gastric Cancer Leeds Experience
    • Total : 211 patients (2001-2004)
    • M1 disease: 67 patients
    • Intervention
      • Obstruction: 20%
      • Bleeding : 7%
      • Perforation: 1%
    • Laparotomy: 9%
    • Median Survival: 7 months
    Sarela A et al. Arch Surg. In press
  • Laparoscopic M1 Gastric Carcinoma
    • Unique group
      • Minimally symptomatic disease
      • Satisfactory functional performance status
    • No-resection is safe and does not appear to shorten survival
      • Quality of life?
    • Role for resection of M1 disease?
  • Laparoscopic Gastric Resection
    • GIST
    • Carcinoma
  • Laparoscopic Gastric Resection GIST
    • Extra-luminal or Exophytic tumors
      • “ Closed” wedge-excision
    • Intra-luminal or Endophytic tumors
      • “ Open” wedge-excision
    • Segmental gastrectomy and anastomosis
  • Laparoscopic Gastric Resection for Carcinoma Aims
    • Entirely laparoscopic
    • Specimen-retrieval via lower abdominal incision
    • Negative primary tumor resection-margins
    • D2 lymphadenectomy
  • Laparoscopic Gastric Resection for Carcinoma Outcome Measures
    • Feasibility
    • Safety
    • Peri-operative benefits
    • Longer-term “mechanical” benefits
      • Incisional hernia
      • Intestinal obstruction
    • Recurrence
    • Survival
  • Laparoscopic Gastrectomy for Carcinoma 2005-2006
    • Selected group: 11 patients
    • 8 men, 3 women
    • Pre-operative stage
      • Early gastric cancer: 6 patients
      • Advanced gastric cancer: 5 patients
    • Selection bias for advanced cancer patients
      • Pulmonary disease
    • Subtotal: 7 patients, Total: 4 patients
    • Conversion: 2 patients
    • Major post-op complication: 3 patients
    • Hospital stay: median 15 days (7-48)
    • Lymph node retrieval: median 22 (10-40)
    • Positive resection margins: 3 patients
    Laparoscopic Gastrectomy 2005-2006
  • Laparoscopic Gastrectomy Complications CT-drain Abscess 3. Lap Subtotal G (C) Re-laparoscopy Chest drain Bleeding O-J leak 2. Lap. Total G Re-laparoscopy Embolisation Duodenal leak Bleeding 1. Lap. Total G Treatment Complications Operation
  • Laparoscopic Gastrectomy for Carcinoma
    • Entirely laparoscopic approach is feasible
    • Steep learning curve
    • Safe (?)
    • Tactile loss for primary tumour extent
    • Lymph node yield > minimum of 15 (AJCC)
    • Patient-selection?